GlobeNewswire by notified

Snam purchases 5 billion cubic metre floating LNG regasification terminal from Golar LNG for US$350 million

Share

The new LNG import terminal will help safeguard Italy’s energy security and diversification

San Donato Milanese (Milan), Bermuda, June 1st 2022 – Snam and Golar LNG Limited (“Golar”) have signed an agreement for the Snam Group to acquire 100% of the share capital of Golar LNG NB 13 Corporation, whose sole asset is a floating storage and regasification unit (FSRU), named “Golar Tundra”, for US$350 million (about €330 million). The transaction was approved by the Golar Board of Directors on May 30th.

The Golar Tundra can operate both as an LNG carrier and as an FSRU. The vessel, built in 2015, has a storage capacity of around 170,000 cubic metres of LNG and a continuous regasification capacity of 5 billion cubic meters per year. In order to maximise its regasification capacity, the vessel will be located in central-northern Italy, close to the areas with greatest gas consumption. The Golar Tundra is expected to start operations as an FSRU during the spring of 2023, subject to completion of authorisation, regulatory processes and the construction of the necessary infrastructure connecting the terminal to the existing gas transport network.

Snam CEO Stefano Venier commented: “With the purchase of the Golar Tundra, Snam is taking a decisive step to enhance the security and diversification of Italy’s energy supplies, in line with its mission. The role of the new FSRU for the benefit of our country will be essential: alone it will contribute to about 6.5% of domestic needs thus bringing the country’s regasification capacity to over 25% of the demand. Snam completed the transaction quickly and effectively in a highly competitive market due to the scarcity of supply and is continuing its efforts to acquire a second FSRU of a similar size, for which exclusive negotiations are currently under way and expected to be finalised by end of June”.

Golar CEO Karl Fredrik Staubo commented: “We are pleased to have reached an agreement for Golar Tundra with Europe’s largest natural gas infrastructure owner. Today’s announced sale marks the second transaction between Golar and Snam for two independent FSRU projects in Italy in a short period of time. We are pleased to work with Snam for the successful start-up of the LNG terminals, and to contribute to Europe’s drive towards energy security. With the sale of Golar Tundra, Golar reinforces its focus on FLNG, enabling efficient production of proven gas reserves allowing customers to further diversify gas supply.”

As part of the transaction, which followed a due diligence assessment of the acquired company and the FSRU itself, Golar will lease Golar Tundra from Snam as an LNG carrier for a limited period of time after closing, and assist Snam in the preparatory work for the installation of the vessel in the selected port. The completion of the transaction occurred simultaneously with the signing of the contracts and will be financed by Snam out of its own resources. In the coming months Snam will begin activities to contract LNG regasification capacity, which will gradually become available from start-up of Golar Tundra as an FSRU expected during the spring of 2023.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended).  All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negative of these terms and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Golar LNG Limited undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable law.

Enquiries:

Golar LNG Limited

Stuart.buchanan@golar.com

+44 207 063 7900

Snam

Ufficio.stampa@snam.it

+39 02 37037273

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo

Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form